Biome signs distribution agreement with Priceline Pharmacy
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
30 May 2022
Biome secures Distribution Agreement with Priceline Pharmacy Group
●
●
●
●
National distribution agreement executed with Priceline Pharmacy
Group
Biome’s distribution network expanded - 370 high volume service
focussed pharmacies added to network
Biome’s existing distribution relationship with Australian
Pharmaceutical Industries (API) is strengthened by this agreement
Biome increases distribution by 50% since IPO on 30th November 2021
Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the
Company’) is pleased to announce it has signed a material distribution agreement
with Australian Pharmaceutical Industries’ (API), Priceline Pharmacy Group
(“Priceline”) to sell its Biome’s Activated Probiotics® as core range in their 370
pharmacies across Australia.
Priceline is one of the largest health and service focussed pharmacy groups in
Australia, backed by both API and its new owners the Wesfarmers group. Priceline
pharmacies offer their patients the highest quality professional products and advice,
aligning well with Biome and its Activated Probiotics range.
Under the new partnership, Priceline is placing an initial allocation of Biome’s
Activated Probiotics® range into its pharmacies around Australia between June and
July 2022. The new partnership will be launched at Priceline Pharmacy’s inaugural
Health Masterclass education series commencing with its members on 20 June
2022.
This distribution agreement further validates Biome’s Activated Probiotics product
range. This materially expands Biome’s distribution network in Australian community
pharmacy with 370 new accounts and access to new customers. This new
partnership will provide further momentum to Biome’s revenue growth.
Priceline Pharmacy General Manager Andrew Vidler said: “We are pleased to be
working with Biome Australia to offer the Activated Probiotics® product range to
our customers. We know that Australians want to make informed decisions about
their health, and as a result, are increasingly seeking scientifically-backed products
to support their health aspirations. Biome’s product range adds to Priceline’s strong
and comprehensive health proposition to our customers.”
Biome Australia Managing Director and Founder Blair Norfolk said: “Distribution
of Biome’s flagship Activated Probiotics® product range via Priceline Pharmacy
presents an exciting opportunity for us to impact more patient lives in Australian
communities. We are proud to support the evolving health service focus of Priceline
Pharmacy with our Activated Probiotics practitioner-only range. Biome’s mission to
improve health outcomes with products accessible to all Australians will be further
supported by this new partnership. “
The Priceline distribution agreement, along with practitioner channel growth, takes
Biome’s distribution footprint to circa 3,000 distribution points. This is a 20% increase
since 31st March 2022, and brings the total increase in distribution points to 50%
since Biome’s IPO on 30th November 2021.
For material terms of the agreement please refer to Appendix A.
- ENDS Approved for release by the Biome Australia board of directors.
About Biome Australia Limited
Biome Australia develops, licenses, commercialises and markets innovative, evidence-based
live biotherapeutics (probiotics) and complementary medicines, many of which are
supported by clinical research. Biome aims to improve health outcomes and quality of life,
and make its products accessible to all.
Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with
some of the world's leading organisations in microbiome research and development, Biome
produced several unique live biotherapeutic (probiotic) products with innovative delivery
technologies that improve their stability and efficacy to create its flagship range of
complementary medicines: Activated Probiotics®.
Supported by clinical research, including randomised double-blind placebo-controlled trials,
Activated Probiotics help prevent and support the management of various health concerns,
including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS.
Through practitioner-only distribution, Biome is committed to educating health professionals
on the newfound systemic health effects of the gut microbiota, helping them to provide
innovative, evidence-based natural medicines for the management of some of humanity's
most prevalent and chronic health concerns. Biome also develops, licenses and distributes a
scientifically formulated, organic nutraceutical range, Activated Nutrients® and a sports
performance and recovery range, Activated X Performance®, which is made exclusively for
professional athletes.
For more information visit: www.biomeaustralia.com
Investor Relations
WE Communications
Hannah Howlett
+61 450 648 064
hhowlett@we-worldwide.com
Media enquiries
media@activated.co
Forward looking statements
This release may contain forward looking statements, including but not limited to projections,
guidance on future revenues, earnings, other potential synergies and estimates and the future
performance of Biome (Forward Looking Statements).
Forward Looking Statements are provided as a general guide only and should not be relied upon as an
indication or guarantee of future performance. Actual results, performance or achievements may
differ materially from those expressed or implied in such Forward Looking Statements and any
projections and assumptions on which these Forward Looking Statements are based. Such statements
may assume the success of Biome's business strategies. You are cautioned not to place undue reliance
on Forward Looking Statements.
The Forward Looking Statements are based on information available to Biome as at the date of this
release. Any Forward Looking Statements containing forward looking financial information provided in
this release is for illustrative purposes only and is not represented as being indicative of Biome's views
on its future financial condition and/or performance. The historic financial information for the
September 2021 financial quarter and revenue figures for October and November 2021 have not been
audited or reviewed by Biome's auditors. Such information should not be taken as a guide for future
performance. Nothing in this release is a promise or representation as to the future. No representation
or warranty, express or implied, is made as to the accuracy, likelihood of achievement or
reasonableness of any Forward Looking Statements contained in this release. Except as required by
law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any
additional or updated information whether as a result of a change in expectations or assumptions,
new information, future events or results or otherwise.
To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in
respect of, and makes no representation or warranty, express or implied as to the fairness, currency,
accuracy, reliability or completeness of information in this release or the accuracy, likelihood of
achievement or reasonableness of any Forward Looking Statements (or any event or results expressed
or implied in any Forward Looking Statements) contained in, implied by, the information in this release
or any part of it, or that this release contains all material information about Biome or which a
prospective investor or purchaser may require in evaluating a possible investment in Biome or
acquisition of securities in Biome.
Investors are strongly cautioned not to place undue reliance on Forward Looking Statements,
particularly in light of the current economic climate and the significant volatility, uncertainty and
disruption caused by the Covid-19 pandemic.
Appendix A
Material Conditions with Priceline Pharmacy Group
Term of Agreement
The term of the agreement is for a 12-month period
commencing on 1 June 2022.
It is anticipated both parties will renegotiate a further 12
- month period on completion of the current
agreement and on an annual basis.
Commercial Terms
In accordance with the terms of the agreement, the
specific commercial terms around pricing remain
confidential.
The Company will keep the market updated on material
business activities as they come to light.
Termination
The agreement does not have any termination for
convenience clauses.
Share your feedback
Discover